Strategies of Overcoming Osimertinib Resistance in EGFR-mutated Non-small Cell Lung Cancer

View Full Paper

Ask AI

Bookmark

Osimertinib resistance mechanisms hinder effective treatment for many NSCLC patients, resulting in treatment challenges.
Key pathways of resistance are categorized as EGFR-dependent and EGFR-independent, affecting therapeutic outcomes.
Therapeutic strategies include novel targeted agents and combination therapies to enhance efficacy in overcoming resistance.
Nanomaterials like selenium nanoparticles show promise in improving drug delivery and addressing resistance pathways.

Discussion

No takes yet. Share an insight, caveat, or question.

Review explores osimertinib resistance mechanisms in NSCLC, highlighting targeted agents and nanomaterials' potential.

Jiang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark